Major histocompatibility complex class I presenting MAGE-A3 and Melan-A peptides (MHC-I/MAGE-A3/Melan-A)

The MHC class I peptide-binding groove presenting MAGE-A3 and Melan-A peptides is a specialized molecular complex essential for the adaptive immune system's ability to detect and eliminate malignant cells. MHC class I molecules, typically HLA-A*02:01 in this context, present short intracellularly derived peptides on the cell surface for surveillance by CD8+ cytotoxic T lymphocytes (Source: UniProt P04439). MAGE-A3 and Melan-A (MART-1) are well-characterized tumor-associated antigens (TAAs) frequently overexpressed in melanoma and other solid tumors while remaining largely absent in healthy tissues, making their peptide-MHC (pMHC) complexes attractive targets for immunotherapy (Source: PubMed 9544474). Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T-cells, peptide vaccines, and bispecific antibodies designed to trigger a potent and specific anti-tumor immune response. However, a significant challenge in targeting these complexes is the risk of off-target toxicity, as seen in historical trials where TCRs cross-reacted with similar peptides in vital organs like the heart or brain (Source: PubMed 23943301).

Other names

HLA-A*02:01/MAGE-A3 complexHLA-A*02:01/Melan-A complexpMHC complexPeptide-MHC class I complexMAGE-A3/HLA-A2Melan-A/HLA-A2MART-1/HLA-A2

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex, leading to the activation of CD8+ cytotoxic T lymphocytes and subsequent lysis of the target tumor cell.